文献速递妇科

基于腹主动脉旁复发风险指导的调强放疗在盆腔淋巴结阳性局部晚期宫颈癌中的作用

Impact of para-aortic recurrence risk-guided intensity-modulated radiotherapy in locally advanced cervical cancer with positive pelvic lymph nodes.
PubMed 文献 · Gynecol Oncol · 2018-01-01

回顾性分析两个三级中心2004至2015年198例盆腔淋巴结阳性、腹主动脉旁淋巴结阴性的FIGO IB2–IVA期宫颈癌患者,比较盆腔放疗与肾静脉下放疗。肾静脉下放疗组腹主动脉旁淋巴结失败率更低(1.3% vs 23.7%,p<0.001),在髂总淋巴结阳性或≥3枚盆腔淋巴结阳性患者中5年腹主动脉旁无复发生存率(100% vs 56.8%,p<0.001)和癌特异生存率(93.9% vs 56.5%,p<0.001)更优,且未增加严重毒性。

要点

  • 肾静脉下放疗组腹主动脉旁淋巴结失败率1.3%,盆腔放疗组23.7%(p<0.001)。
  • 髂总淋巴结阳性或≥3枚盆腔淋巴结阳性者,肾静脉下放疗5年腹主动脉旁无复发生存率100% vs 56.8%(p<0.001)。
  • 同组患者肾静脉下放疗5年癌特异生存率93.9% vs 56.5%(p<0.001),严重毒性未增加。

核心结论

  • 基于盆腔淋巴结位置和数量的风险导向放疗野可优化盆腔淋巴结阳性宫颈癌的结局。

研究设计与样本

  • 回顾性研究,纳入2004至2015年两个三级中心198例FIGO IB2–IVA期、盆腔淋巴结阳性且腹主动脉旁淋巴结阴性的宫颈癌患者。
  • 所有患者接受调强放疗的盆腔放疗或肾静脉下放疗;肾静脉下放疗将盆腔放疗野头侧延伸至左肾静脉水平;处方剂量45–50.4Gy,每次1.8Gy。

主要发现

  • 盆腔放疗组118例,肾静脉下放疗组80例;肾静脉下放疗组FIGO分期更晚、髂总淋巴结阳性及盆腔淋巴结数量更多。
  • 中位随访63个月(范围7–151个月)。
  • 腹主动脉旁淋巴结失败:盆腔放疗组28例(23.7%) vs 肾静脉下放疗组1例(1.3%)(p<0.001)。
  • 髂总淋巴结阳性或≥3枚盆腔淋巴结阳性患者:肾静脉下放疗较盆腔放疗改善5年腹主动脉旁无复发生存率(100% vs 56.8%,p<0.001)和癌特异生存率(93.9% vs 56.5%,p<0.001)。
  • 髂总动脉分叉以下淋巴结阳性且1–2枚盆腔淋巴结阳性患者中,上述结局无显著差异;肾静脉下放疗未增加严重毒性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: A previous study has suggested the benefit of sub-renal vein radiotherapy (SRVRT) for pelvic lymph node (PLN)-positive cervical cancer. In order to better select patients for SRVRT, this study aimed to evaluate the value of a risk-based radiation field based on PLN location and number in PLN-positive cervical cancer. METHODS: We reviewed 198 patients with FIGO stage IB2-IVA cervical cancer, positive PLNs, and negative para-aortic lymph nodes (PALNs) from 2004 to 2015 at two tertiary centers. All patients underwent pelvic radiotherapy (PRT) or SRVRT with IMRT. The SRVRT extended the PRT field cranially to the level of the left renal vein. The prescribed doses were 45-50.4Gy in 1.8Gy per fraction. RESULTS: Overall, 118 and 80 patients underwent PRT and SRVRT, respectively. The SRVRT group had more advanced disease based on FIGO stage, common iliac PLNs, and number of PLNs. The median follow-up was 63months (range: 7-151months). PALN failure was experienced by 28 patients (23.7%) in the PRT group and 1 patient (1.3%) in the SRVRT group (p<0.001). Compared with PRT, SRVRT significantly improved 5-year PALN recurrence-free survival (56.8% vs. 100%, p<0.001) and cancer-specific survival (56.5% vs. 93.9%, p<0.001) among patients with common iliac PLNs or ≥3 PLNs. No significant differences were observed in these outcomes among patients with PLNs below the common iliac bifurcation and 1-2 PLNs. The SRVRT did not increase severe toxicities. CONCLUSIONS: Risk-based radiation field based on PLN location and number could optimize outcomes for PLN-positive cervical cancer.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Lee J, Lin JB, Chang CL, et al. Impact of para-aortic recurrence risk-guided intensity-modulated radiotherapy in locally advanced cervical cancer with positive pelvic lymph nodes. Gynecol Oncol. 2018. PMID: 29269219. doi:10.1016/j.ygyno.2017.12.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。